Anifrolumab

Article Details

Citation
Copy to clipboard

Bui A, Sanghavi D

Anifrolumab

.

PubMed ID
32310439 [ View in PubMed
]
Abstract

Anifrolumab is a novel investigational agent used to manage and treat systemic lupus erythematosus (SLE). It is a fully-humanized IgG1k monoclonal antibody that inhibits cellular signaling transmitted by the type 1 interferon receptor (IFNAR1) upon activation. This activity will highlight the indications, mechanism of action, pharmacokinetics, adverse events, and contraindications of anifrolumab. This activity will describe anifrolumab's role in therapy and the clinical approach interprofessional teams can take to treat SLE effectively.

DrugBank Data that Cites this Article

Drugs